PEAK1 and neoplasm: Genetic knockdown of eIF5A inhibited PDAC cell growth in vitro and orthotopic tumor formation in vivo, potentially through pseudopodium-enriched atypical kinase 1 (PEAK1), which is essential to PDAC tumor growth, metastasis, and gemcitabine resistance [174].